Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM-1340 in Advanced Solid Tumors
NCT07890246Phase 1Not yet recruiting
- Sponsor
- Immunome
- Start
- Nov 2026
- Primary completion
- Sep 2030
01
Overview
Phase 1, open-label trial of IM-1340 in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 2 more (2 arms), sponsored by Immunome. Primary endpoint: Safety and tolerability of IM-1340. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
IM-1340
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT07890246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890246.